Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your genes could hold the key to better depression treatment

NCT ID NCT07738497

Diagnosis Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This trial is testing whether using a genetic test to choose antidepressants leads to better outcomes for people with major depressive disorder. Half of the 220 participants will have their treatment guided by a cheek swab that analyzes genes affecting drug metabolism, while the other half will receive standard care. The study will compare response rates, side effects, and how often medication adjustments are needed over 12 weeks, with the goal of moving toward more personalized depression care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pharmacogenomic testing (genetic test from a cheek swab) to guide antidepressant selection
What this could lead to
If successful, this could make depression treatment more personalized, helping doctors choose the right antidepressant based on a patient's genes, potentially improving response rates and reducing side effects.
What could go wrong
The trial is relatively small and early, and genetic testing may not always predict real-world drug response. Results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 220 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

14 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Clinical diagnosis of Major Depressive Disorder (MDD) according to DSM-5 criteria 2. Age between 18 and 60 years 3. Baseline HAMD-17 total score ≥ 17 4. Ability to provide written informed consent Exclusion Criteria: 1. History of other psychiatric disorders (e.g., bipolar disorder, schizophrenia) 2. Presence of severe physical illnesses or major central nervous system diseases 3. History of sedative-hypnotic, alcohol, or substance abuse 4. Pregnancy, lactation, or planning to become pregnant during the study 5. Significant abnormalities in ECG, complete blood count, or liver/kidney/thyroid function tests

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depression - major depressive disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Depression Inflammation major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depression - major depressive disorder

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.